Investigational Studies

LONDON, March 07, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH), (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the appointment of Scott Giacobello as Chief Financial Officer on 6 March 2017. Reporting to GW’s Chief Executive Officer […]

LONDON, March 07, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (GWPH), (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the appointment of Scott Giacobello as Chief Financial Officer on 6 March 2017. Reporting to GW’s Chief Executive Officer […]

LONDON, March 02, 2017 — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the Cowen and Company 37th Annual Healthcare Conference on Wednesday, 8 March, 2017 […]

LONDON, March 02, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the Cowen and Company 37th Annual Healthcare Conference on Wednesday, 8 […]

LONDON, March 02, 2017 — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the Cowen and Company 37th Annual Healthcare Conference on Wednesday, 8 March, 2017 […]

Major biotech stocks like Amgen AMGN and Gilead GILD reported fourth quarter results — while both topped estimates, revenue outlook fell short of expectations. Recap of the Week’s Most Important Stories Amgen Delivers Strong Quarter but Sales Guidance Falls Short: Amgen’s fourth quarter results were better-than-expected with the company beating on all fronts. The company […]

by

Cambridge based GW Pharmaceuticals has now been granted Orphan Drug Designation from FDA for Cannabidiol drug to treat a 3rd rare genetic form of epilepsy. GW Pharmaceuticals has been granted Orphan Drug Designation for cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). Epidiolex is a liquid formulation of pure plant-derived CBD, which is in development for […]

by

Major biotech stocks like Amgen AMGN and Gilead GILD reported fourth quarter results — while both topped estimates, revenue outlook fell short of expectations. Recap of the Week’s Most Important Stories Amgen Delivers Strong Quarter but Sales Guidance Falls Short: Amgen’s fourth quarter results were better-than-expected with the company beating on all fronts. The company […]

by

Submit the press release Lead program in Graft versus Host Disease (“GvHD”), a life-threatening condition that can occur following stem cell or bone marrow transplantationFour Phase 2 clinical studies evaluating CBD in the prevention and treatment of GvHDOrphan drug designations (“ODD”) granted in the U.S. and EuropeAdvancing towards FDA Phase 2b clinical studiesVANCOUVER, British Columbia, […]

by

Submit the press release Lead program in Graft versus Host Disease (“GvHD”), a life-threatening condition that can occur following stem cell or bone marrow transplantationFour Phase 2 clinical studies evaluating CBD in the prevention and treatment of GvHDOrphan drug designations (“ODD”) granted in the U.S. and EuropeAdvancing towards FDA Phase 2b clinical studiesVANCOUVER, British Columbia, […]

by